Larry Schlabach

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non–small-cell lung cancer (a Vanderbilt cancer center affiliate network study)

Hak Choy, Russell F. DeVore, Kenneth R. Hande et al. · International Journal of Radiation Oncology*Biology*Physics · 2000 · 101 citations

Radiation Medicine, Radiation Therapy, Medicine +6

Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer

John V. Heymach, David H. Johnson, Fadlo R. Khuri et al. · Annals of Oncology · 2004 · 89 citations · Full text

Oncology, Medicine, Pathology +8

In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity.

Roger L. Berkow, Larry Schlabach, Robin E. Dodson et al. · PubMed · 1993 · 45 citations

Immunology, Immunotherapy, Tumor Biology +18

Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.

Madan Jagasia, Corey J. Langer, Douglas H. Johnson et al. · PubMed · 2001 · 41 citations

Tumor Biology, Advanced Nsclc, Therapeutic Synergy +14